Systemic sclerosis & Raynaud's
Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index
Authors' conclusion
We present a novel instrument to quantify the burden of disease activity in SSc.
Study context
- Population
- Patients with Systemic Sclerosis (SSc) in the Australian Scleroderma Cohort Study and the Canadian Scleroderma Research Group Study
- Participants
- 1,254 vs 1,103
- Comparison
- Australian Scleroderma Cohort Study (ASCS) vs Canadian Scleroderma Research Group Study
- ASCSn = 1,254
- Canadian Scleroderma Research Group Studyn = 1,103
- Outcome
- Development of the SCTC-AI
Methodological detailsconsensus methodology, Delphi survey, time-dependent Cox proportional hazards regression, external validation, Disease activity defined by consensus as "aspects of disease that are reversible, or can be arrested, with time and, or effective therapy."
- Consensus methodology
- Delphi survey
- Time-dependent Cox proportional hazards regression
- External validation
- Disease activity defined by consensus as "aspects of disease that are reversible, or can be arrested, with time and, or effective therapy."
Performance
As reported in the abstract
- Provisional SCTC-AI items generated
- 141
- Rounds of Delphi survey
- 3
- Items in final index
- 24
- Maximum possible score
- 140
- Graded relationship between disease activity scores and survival in external cohort
- P < 0.01
Original publication
Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index. Arthritis Rheumatol. Published 26 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →